Byrne Asset Management’s AstraZeneca AZN Stock Holding History

Byrne Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.4K	Sell	72 -75	-51%	-$12.5K	0.01%	437
2026 Q2	$27.9K	Hold	147	–	–	0.02%	337
2026 Q1	$29K	Sell	147 -3	-2%	-$578	0.02%	317
2025 Q4	$27.6K	Buy	+150	New	+$26.3K	0.02%	323
2025 Q3	–	Sell	-150	Closed	-$22.7K	–	324
2025 Q2	$21K	Hold	150	–	–	0.01%	326
2025 Q1	$22.1K	Hold	150	–	–	0.02%	330
2024 Q4	$19.7K	Hold	150	–	–	0.01%	294
2024 Q3	$23.4K	Hold	150	–	–	0.02%	277
2024 Q2	$23.5K	Hold	150	–	–	0.02%	268
2024 Q1	$20.3K	Hold	150	–	–	0.01%	296
2023 Q4	$20.2K	Hold	150	–	–	0.02%	289
2023 Q3	$20K	Hold	150	–	–	0.02%	267
2023 Q2	$21K	Sell	150 -176	-54%	-$25.9K	0.01%	316
2023 Q1	$58K	Hold	326	–	–	0.04%	212
2022 Q4	$56.9K	Buy	326 +176	+117%	+$22.1K	0.04%	210
2022 Q3	$16K	Hold	150	–	–	0.01%	318
2022 Q2	$20K	Hold	150	–	–	0.01%	275
2022 Q1	$20K	Hold	150	–	–	0.01%	306
2021 Q4	$17K	Buy	+150	New	+$17.6K	0.01%	309

Other funds holding AZN

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

PAS

Professional Advisory Services Vero Beach, Florida $837M AUM 20.44% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return

PNC

Park National Corp Newark, Ohio $3.69B AUM 18.32% 1-Year Est. Return

CCM

Cox Capital Management Andover, Massachusetts $179M AUM 28.94% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CNBT

Canandaigua National Bank & Trust Canandaigua, New York $1.15B AUM

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

Parrish Capital Kennesaw, Georgia $103M AUM 35.11% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Byrne Asset Management's AZN Position: Q3 2026 in Review

Byrne Asset Management reduced its AstraZeneca (AZN) stake by 51% in Q3 2026, selling an estimated $12.5K and leaving 72 shares worth $11.4K. The position accounts for 0.01% of the portfolio, ranked #437.

Byrne Asset Management first reported a position in AZN in Q4 2021 and has held it in 19 quarters since. The position peaked at $58K in Q1 2023. 47 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Byrne Asset Management held 72 shares of AstraZeneca worth $11.4K as of Q3 2026.
Byrne Asset Management sold 75 AstraZeneca shares in Q3 2026, an estimated $12.5K.
AstraZeneca made up 0.01% of Byrne Asset Management's portfolio in Q3 2026, its #437 holding.
Byrne Asset Management first reported a position in AstraZeneca in Q4 2021 and has held it in 19 quarters since.
Byrne Asset Management's AstraZeneca position peaked at $58K in Q1 2023.
47 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Byrne Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.